Target Antigen Attributes and Their Contributions to Clinically Approved Antibody-Drug Conjugates (ADCs) in Haematopoietic and Solid Cancers
Cancers · 19.03.2023 · 15 (6) · 1845
DOI: 10.3390/cancers15061845 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 19.03.2023. Verfasst von Benjamina Esapa und 5 weiteren Autor:innen. Beteiligte Einrichtung: St. John's Institute of Dermatology, School of Basic & Medical Biosciences, King's College London, Guy's Hospital, London SE1 9RT, UK. Die Arbeit wurde bisher 89-mal zitiert (Crossref) und nennt 220 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK, National Institute for Health Research, Guy's and St Thomas' Charity.
Abstract (Originalsprache)
Antibody drug conjugates (ADCs) are powerful anti-cancer therapies comprising an antibody joined to a cytotoxic payload through a chemical linker. ADCs exploit the specificity of antibodies for their target antigens, combined with the potency of cytotoxic drugs, to selectively kill target antigen-expressing tumour cells. The recent rapid advancement of the ADC field has so far yielded twelve and eight ADCs approved by the US and EU regulatory bodies, respectively. These serve as effective targeted treatments for several haematological and solid tumour types. In the development of an ADC, the judicious choice of an antibody target antigen with high expression on malignant cells but restricted expression on normal tissues and immune cells is considered crucial to achieve selectivity and potency while minimising on-target off-tumour toxicities. Aside from this paradigm, the selection of an antigen for an ADC requires consideration of several factors relating to the expression pattern and biological features of the target antigen. In this review, we discuss the attributes of antigens selected as targets for antibodies used in clinically approved ADCs for the treatment of haematological and solid malignancies. We discuss target expression, functions, and cellular kinetics, and we consider how these factors might contribute to ADC efficacy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- St. John's Institute of Dermatology, School of Basic & Medical Biosciences, King's College London, Guy's Hospital, London SE1 9RT, UK.
- Breast Cancer Now Research Unit, School of Cancer & Pharmaceutical Sciences, King's College London, Guy's Cancer Centre, London SE1 9RT, UK.
- Institute of Pharmaceutical Science, School of Cancer and Pharmaceutical Sciences, King's College London, London SE1 9NH, UK.
ORCID-Profile: Jiexuan Jiang, Anthony Cheung, David E Thurston, Sophia N Karagiannis
Förderung
- Cancer Research UK
- National Institute for Health Research
- Guy's and St Thomas' Charity
- Medical Research Council
- Breast Cancer Now
- Biotechnology and Biological Sciences Research Council
- the National Institute for Health and Care Research (NIHR) Biomedical Research Centre (BRC)
- the Biotechnology and Biological Sciences Research Council
Zitieren
APA
Esapa, B., Jiang, J., Cheung, A., Chenoweth, A., Thurston, D. E., & Karagiannis, S. N. (2023). Target Antigen Attributes and Their Contributions to Clinically Approved Antibody-Drug Conjugates (ADCs) in Haematopoietic and Solid Cancers. Cancers, 15(6), 1845. https://doi.org/10.3390/cancers15061845
Vancouver
Esapa B, Jiang J, Cheung A, Chenoweth A, Thurston DE, Karagiannis SN. Target Antigen Attributes and Their Contributions to Clinically Approved Antibody-Drug Conjugates (ADCs) in Haematopoietic and Solid Cancers. Cancers. 2023;15(6):1845. doi:10.3390/cancers15061845
BibTeX
@article{Esapa2023,
author = {Esapa, Benjamina and Jiang, Jiexuan and Cheung, Anthony and Chenoweth, Alicia and Thurston, David E and Karagiannis, Sophia N},
title = {Target Antigen Attributes and Their Contributions to Clinically Approved Antibody-Drug Conjugates (ADCs) in Haematopoietic and Solid Cancers},
journal = {Cancers},
year = {2023},
volume = {15},
number = {6},
pages = {1845},
doi = {10.3390/cancers15061845}
}
EUVIMED